{
    "clinical_study": {
        "@rank": "124248", 
        "brief_summary": {
            "textblock": "The aim of this registry is to provide information, in day-to-day practice, on Plerixafor\n      prescription modalities in France, over a 13-month period in order to address the health\n      authorities' request."
        }, 
        "brief_title": "Registry of Patients Treated With Plerixafor (Mozobil\u00ae) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Bone Marrow / Autologous Transplants", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients treated with Plerixafor for autologous transplantation between November 2011\n             and November 2012\n\n          -  Patients who have been informed and who have given their written consent for the\n             access to their medical file\n\n        Exclusion Criteria:\n\n          -  Patients already included in a Plerixafor ongoing clinical trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "The selection of the registry's participants will be based on an exhaustive request of all\n        apheresis centers distributed in the French territory."
            }
        }, 
        "enrollment": {
            "#text": "262", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738373", 
            "org_study_id": "MOZ22510"
        }, 
        "intervention": {
            "description": "Plerixafor will be prescribed independently by the physician, according to usual practice.", 
            "intervention_name": "Plerixafor", 
            "intervention_type": "Drug", 
            "other_name": "Mozobil\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "JM 3100"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "autologous stem cell transplantation", 
            "lymphoma", 
            "multiple myeloma"
        ], 
        "lastchanged_date": "March 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Marseille", 
                    "country": "France"
                }
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study", 
        "overall_official": {
            "affiliation": "Genzyme, a Sanofi Company", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Direction G\u00e9n\u00e9rale de la Sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "The characteristics of the patients who received treatment", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }, 
            {
                "measure": "Dosage of treatment", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }, 
            {
                "measure": "Number of CD34+ cells collected following treatment", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }, 
            {
                "measure": "Number of patients with the existence of one or more predictive factors of poor mobilisation", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }, 
            {
                "measure": "Duration of treatment", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }, 
            {
                "measure": "Associated treatments", 
                "safety_issue": "No", 
                "time_frame": "13 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738373"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Genzyme, a Sanofi Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2013"
    }
}